Look Out: Moderna Could Have an Even Better COVID Vaccine on the Way
Moderna (NASDAQ: MRNA) already markets a COVID-19 vaccine that's highly effective. The vaccine is also poised to be highly lucrative with the biotech projecting 2021 sales of more than $18 billion. But Moderna could have an even better COVID-19 vaccine on the way. In this Motley Fool Live video, recorded on March 17, Motley Fool contributors Keith Speights and Brian Orelli discuss how Moderna's next-generation vaccine in development could be a winner in the marketplace.
Source Fool.com
